GC protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Thyer, Lynda ^a   Ward, Emma ^a   Smith, Rodney ^a   Branca, Jacopo J V ^b   Morucci, Gabriele ^b   Gulisano, Massimo ^b   Noakes, David ^c   Eslinger, Robert ^d   Pacini, Stefania ^b  

^a Macro Innovations Ltd   (United Kingdom)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Immuno Biotech Ltd   (United Kingdom)

^d VA Reno Medical Center   (United States)

Author keywords

Cancer; Complementary medicine; Immunotherapy; Macrophages; Vitamin D

Indexed keywords

ALPHA N ACETYLGALACTOSAMINIDASE; GC PROTEIN DERIVED MACROPHAGE ACTIVATING FACTOR; MOLECULAR THERAPY AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLICULAR LYMPHOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LARYNX CANCER; LYMPHOMA; MALE; OLIGODENDROGLIOMA; OVARY CANCER; PROSTATE CANCER; RETROSPECTIVE STUDY; TONGUE CARCINOMA; TREATMENT OUTCOME;

EID: 84885827492     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25769     Document Type: Article

References (22)

1. Yamamoto N, Naraparaju VR, Moore M, Brent LH. Deglycosylation of serum vitamin D3-binding protein by alpha-N-acetylgalactosaminidase detected in the plasma of patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1997; 82:290- 8; PMID:9073553; http://dx.doi.org/10.1006/ clin.1996.4320
2. Mohamad SB, Nagasawa H, Uto Y, Hori H. Tumor cell alpha-N-acetylgalactosaminidase activity and its involvement in GcMAF-related macrophage activation. Comp Biochem Physiol A Mol Integr Physiol 2002; 132:1-8; PMID:12062184; http://dx.doi.org/10.1016/ S1095-6433(01)00522-0
3. Greco M, Mitri MD, Chiriacò F, Leo G, Brienza E, Maffia M. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity. Cancer Lett 2009; 283:222-9; PMID:19394758; http://dx.doi.org/10.1016/j.canlet. 2009.04.001
4. Reddi AL, Sankaranarayanan K, Arulraj HS, Devaraj N, Devaraj H. Serum alpha-N-acetylgalactosaminidase is associated with diagnosis/prognosis of patients with squamous cell carcinoma of the uterine cervix. Cancer Lett 2000; 158:61-4; PMID:10940510; http://dx.doi. org/10.1016/S0304-3835(00)00502-4
5. Yamamoto N, Suyama H, Yamamoto N, Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer 2008; 122:461-7; PMID:17935130; http://dx.doi. org/10.1002/ijc.23107
6. Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage- activating factor, GcMAF. Cancer Immunol Immunother 2008; 57:1007-16; PMID:18058096; http://dx.doi.org/10.1007/s00262-007-0431-z
7. Yamamoto N, Suyama H, Yamamoto N. Immunotherapy for Prostate Cancer with Gc Protein- Derived Macrophage-Activating Factor, GcMAF. Transl Oncol 2008; 1:65-72; PMID:18633461
8. Nonaka K, Onizuka S, Ishibashi H, Uto Y, Hori H, Nakayama T, et al. Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice. J Surg Res 2012; 172:116-22; PMID:20855083; http:// dx.doi.org/10.1016/j.jss.2010.07.057
9. Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, et al. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One 2010; 5:e13428; PMID:20976141; http:// dx.doi.org/10.1371/journal.pone.0013428
10. Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M. Effects of vitamin D-binding protein-derived macrophage- activating factor on human breast cancer cells. Anticancer Res 2012; 32:45-52; PMID:22213287
11. Kalkunte S, Brard L, Granai CO, Swamy N. Inhibition of angiogenesis by vitamin D-binding protein: characterization of anti-endothelial activity of DBP-maf. Angiogenesis 2005; 8:349-60; PMID:16400520; http://dx.doi.org/10.1007/s10456-005-9024-7
12. Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M. Gc protein-derived macrophage-activating factor (GcMAF) stimulates cAMP formation in human mononuclear cells and inhibits angiogenesis in chick embryo chorionallantoic membrane assay. Cancer Immunol Immunother 2011; 60:479-85; PMID:21170647; http://dx.doi.org/10.1007/s00262-010-0953-7
13. Pacini S, Morucci G, Punzi T, Gulisano M, Ruggiero M, Amato M, et al. Effect of paricalcitol and GcMAF on angiogenesis and human peripheral blood mononuclear cell proliferation and signaling. J Nephrol 2012; 25:577-81; PMID:21956771; http://dx.doi. org/10.5301/jn.5000035
14. Yamamoto N, Naraparaju VR, Urade M. Prognostic utility of serum alpha-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res 1997; 57:295-9; PMID:9000571
15. Yamamoto N, Lindsay DD, Naraparaju VR, Ireland RA, Popoff SN. A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats. J Immunol 1994; 152:5100-7; PMID:8176226
16. Nunn R. Mere anecdote: evidence and stories in medicine. J Eval Clin Pract 2011; 17:920-6; PMID:21815971; http://dx.doi.org/10.1111/j.1365- 2753.2011.01727.x
17. Yamamoto N, Ushijima N, Koga Y. Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). J Med Virol 2009; 81:16-26; PMID:19031451; http://dx.doi. org/10.1002/jmv.21376
18. Bradstreet JJ, Vogelaar E, Thyer L. Initial observations of elevated alpha-N-acetylgalactosaminidase activity associated with autism and observed reductions from GC protein-macrophage activating factor injections. Autism Insights 2012; 4:31-8; http://dx.doi. org/10.4137/AUI.S10485
19. Fabris A, Biagioni P, Punzi T, Morucci G, Gulisano M, Pacini S, et al. Role of angiotensin-converting enzyme and vitamin D receptor gene polymorphisms in cancer anorexia-cachexia syndrome. Am J Immunol 2012; 8:65-70
20. Rehder DS, Nelson RW, Borges CR. Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci 2009; 18:2036-42; PMID:19642159; http://dx.doi.org/10.1002/pro.214
21. Inui T, Kuchiike D, Kubo K, Mette M, Uto Y, Hori H, et al. Clinical Experience of Integrative Cancer Immunotherapy with GcMAF. Anticancer Res 2013; 33:2917-9; PMID:23780980
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54; PMID:942051; http:// dx.doi.org/10.1016/0003-2697(76)90527-3